{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:25Z","timestamp":1787027905171,"version":"build-2736575974"},"reference-count":97,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/023xf2a37","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Given ongoing uncertainty about the benefits and harms of prostate-specific antigen (PSA) screening, this systematic review updates the evidence to inform guideline recommendations for adults aged \u2265 18 years in primary care. We searched multiple bibliographic databases from inception to 30 May 2022, with an update on 24 July 2024, for randomized controlled trials (RCTs) and comparative observational studies evaluating PSA-based screening with or without adjunctive technologies such as magnetic resonance imaging (MRI). Studies were selected in duplicate, with data extraction and quality assessment verified by a second reviewer; risk of bias and evidence certainty were assessed using study design-specific tools and GRADE. Four RCTs and one cohort study (17 articles) were included: ERSPC, PLCO and CAP compared PSA screening with no screening, while STHLM3-MRI evaluated a risk-based test combined with MRI targeted biopsy. Meta-analysis showed 0.96 fewer prostate cancer deaths per 1000 individuals invited to screen, corresponding to a 12% relative reduction over 9.5\u201322 years (RR 0.88, 95% CI 0.81\u20130.95). One trial estimated 2.3% to 10.3% overdiagnosis over 10\u201314 years. Overall certainty of evidence was low or very low. PSA screening may offer a small mortality benefit, but uncertainty and variable harms limit confidence, underscoring the need for high-quality evidence, particularly for MRI and risk-based screening strategies.<\/jats:p>","DOI":"10.3390\/curroncol33040199","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:23:17Z","timestamp":1774963397000},"page":"199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review"],"prefix":"10.3390","volume":"33","author":[{"given":"Alexandria","family":"Bennett","sequence":"first","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyati","family":"Vyas","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-8895","authenticated-orcid":false,"given":"Nicole","family":"Shaver","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-6883","authenticated-orcid":false,"given":"Faris","family":"Almoli","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taddele","family":"Kibret","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-1781","authenticated-orcid":false,"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[{"name":"Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Del Giudice","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-3758","authenticated-orcid":false,"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8N 3Z5, Canada"},{"name":"Department of Oncology, McMaster University, Hamilton, ON L8V5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-9238","authenticated-orcid":false,"given":"Becky","family":"Skidmore","sequence":"additional","affiliation":[{"name":"Independent Information Specialist, Ottawa, ON K1T 3Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Brouwers","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-5531","authenticated-orcid":false,"given":"Julian","family":"Little","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moher","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"},{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/cncr.20408","article-title":"Human Prostate Cancer Risk Factors","volume":"101","author":"Bostwick","year":"2004","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/gim.2015.125","article-title":"Multigene Panels in Prostate Cancer Risk Assessment: A Systematic Review","volume":"18","author":"Little","year":"2016","journal-title":"Genet. Med."},{"key":"ref_5","first-page":"807","article-title":"Prostate Cancer: 3. Individual Risk Factors","volume":"159","author":"Gallagher","year":"1998","journal-title":"CMAJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/aja.2011.150","article-title":"The Role of BRCA1 and BRCA2 in Prostate Cancer","volume":"14","author":"Castro","year":"2012","journal-title":"Asian J. Androl."},{"key":"ref_7","first-page":"S92","article-title":"The Burden of Prostate Cancer in Canada","volume":"3","author":"Fradet","year":"2009","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","article-title":"Characterizing Prostate Cancer Risk through Multi-Ancestry Genome-Wide Discovery of 187 Novel Risk Variants","volume":"55","author":"Wang","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Crocetto, F., Barone, B., Caputo, V.F., Fontana, M., de Cobelli, O., and Ferro, M. (2021). BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050908"},{"key":"ref_10","first-page":"3866","article-title":"The Worldwide Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies","volume":"15","author":"Haas","year":"2008","journal-title":"Can. J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black Race with Prostate Cancer\u2013Specific and Other-Cause Mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_12","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2105\/AJPH.2008.150508","article-title":"Smoking as a Risk Factor for Prostate Cancer: A Meta-Analysis of 24 Prospective Cohort Studies","volume":"100","author":"Huncharek","year":"2010","journal-title":"Am. J. Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.euf.2014.10.002","article-title":"Smoking and Prostate Cancer: A Systematic Review","volume":"1","author":"Andriole","year":"2015","journal-title":"Eur. Urol. Focus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-118-10-199305150-00007","article-title":"Risk Factors for Prostate Cancer","volume":"118","author":"Pienta","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_16","unstructured":"(2021, May 21). Canadian Population Attributable Risk of Cancer (ComPARe) Study Cancer Types. Available online: https:\/\/data.prevent.cancer.ca\/current\/cancer-types."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15430\/JCP.2019.24.2.91","article-title":"Occupational Risk Factors for Prostate Cancer: A Meta-Analysis","volume":"24","author":"Krstev","year":"2019","journal-title":"J. Cancer Prev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e3493","DOI":"10.1097\/MD.0000000000003493","article-title":"Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies","volume":"95","author":"Dai","year":"2016","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Huang, J., Sun, J., Wang, K., Zheng, L., Fan, Y., and Qian, B. (2024). Causal Relationship between Prostatic Diseases and Prostate Cancer: A Mendelian Randomization Study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12551-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/ijc.23713","article-title":"Lower Urinary Tract Symptoms and Risk of Prostate Cancer: The HUNT 2 Cohort, Norway","volume":"123","author":"Martin","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, X., Yang, H., Yin, C., Wu, Y., and Chen, X. (2025). Predictive Factors of Incidental Prostate Cancer in Patients Undergoing Surgery for Presumed Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-Analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1561675"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrurol.2012.192","article-title":"The Link between Benign Prostatic Hyperplasia and Prostate Cancer","volume":"10","author":"Bojesen","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"ref_23","unstructured":"(2020, May 20). Prostate-Specific Antigen (PSA) Test\u2014Canadian Cancer Society. Available online: https:\/\/cancer.ca\/en\/treatments\/tests-and-procedures\/prostate-specific-antigen-psa-test."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5489\/cuaj.4888","article-title":"Canadian Urological Association Recommendations on Prostate Cancer Screening and Early Diagnosis","volume":"11","author":"Rendon","year":"2017","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S603","DOI":"10.1016\/j.ijrobp.2012.07.1609","article-title":"Referral of Suspected Prostate Cancer by Family Physicians and Other Primary Care Providers","volume":"84","author":"Young","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.eururo.2010.02.003","article-title":"Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection","volume":"57","author":"Jansen","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mayocp.2015.07.030","article-title":"Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing","volume":"Volume 91","author":"Binette","year":"2016","journal-title":"Mayo Clinic Proceedings"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1370\/afm.2205","article-title":"Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis","volume":"16","author":"Naji","year":"2018","journal-title":"Ann. Fam. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.juro.2017.10.021","article-title":"Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer","volume":"199","author":"Halpern","year":"2018","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1155\/2012\/681357","article-title":"A Survey of Digital Rectal Examination Training in Canadian Medical Schools","volume":"26","author":"Nensi","year":"2012","journal-title":"Can. J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-Yr Follow-up of the European Randomized Study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate Cancer Screening with Prostate-Specific Antigen (PSA) Test: A Systematic Review and Meta-Analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-Up","volume":"104","author":"Andriole","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3399\/bjgp18X699689","article-title":"Lower Urinary Tract Symptoms and Prostate Cancer: Is PSA Testing in Men with Symptoms Wise?","volume":"68","author":"Just","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and Overtreatment of Prostate Cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/jnci\/djp278","article-title":"Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986\u20132005","volume":"101","author":"Welch","year":"2009","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/JU.0000000000001578","article-title":"Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review","volume":"205","author":"Wilt","year":"2021","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu525","article-title":"Do Prostate Cancer Risk Models Improve the Predictive Accuracy of PSA Screening? A Meta-Analysis","volume":"26","author":"Louie","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhen, L., Liu, X., Yegang, C., Yongjiao, Y., Yawei, X., Jiaqi, K., Xianhao, W., Yuxuan, S., Rui, H., and Wei, Z. (2019). Accuracy of Multiparametric Magnetic Resonance Imaging for Diagnosing Prostate Cancer: A Systematic Review and Meta-Analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6434-2"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"62ps55","DOI":"10.1126\/scitranslmed.3001861","article-title":"Personalized Prostate Cancer Screening: Improving PSA Tests with Genomic Information","volume":"2","author":"Witte","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41588-024-02068-z","article-title":"Genome-Wide Association Study of Prostate-Specific Antigen Levels in 392,522 Men Identifies New Loci and Improves Prediction across Ancestry Groups","volume":"57","author":"Hoffmann","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gilbert, R., Martin, R.M., Evans, D.M., Tilling, K., Davey Smith, G., Kemp, J.P., Lane, J.A., Hamdy, F.C., Neal, D.E., and Donovan, J.L. (2015). Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136735"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41591-023-02277-9","article-title":"Genetically Adjusted PSA Levels for Prostate Cancer Screening","volume":"29","author":"Kachuri","year":"2023","journal-title":"Nat. Med."},{"key":"ref_46","unstructured":"Devlin, H., and Correspondent, H.D.S. (The Guardian, 2025). At-Home Saliva Test for Prostate Cancer Better than Blood Test, Study Suggests, The Guardian."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1503\/cmaj.140703","article-title":"Recommendations on Screening for Prostate Cancer with the Prostate-Specific Antigen Test","volume":"186","author":"Bell","year":"2014","journal-title":"CMAJ"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"718","DOI":"10.7326\/M14-2326","article-title":"High Value Care Task Force of the American College of Physicians Screening for Cancer: Advice for High-Value Care from the American College of Physicians","volume":"162","author":"Wilt","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_49","unstructured":"American Academy of Family Physicians (AAFP) (2021, March 30). Clinical Preventive Service Recommendation: Prostate Cancer. Available online: https:\/\/www.aafp.org\/family-physician\/patient-care\/clinical-recommendations\/all-clinical-recommendations\/prostate-cancer.html."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-Specific Antigen\u2013Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"key":"ref_51","unstructured":"(2021, March 30). UK National Screening Committee the UK NSC Recommendation on Prostate Cancer Screening\/PSA Testing in Men over the Age of 50, Available online: https:\/\/view-health-screening-recommendations.service.gov.uk\/prostate-cancer\/."},{"key":"ref_52","unstructured":"Harris, M. (2026, March 12). UK NSC Opens Consultation on Draft Prostate Cancer Screening Recommendation\u2014UK National Screening Committee, Available online: https:\/\/nationalscreening.blog.gov.uk\/2025\/11\/28\/uk-nsc-opens-consultation-on-draft-prostate-cancer-screening-recommendation\/."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"k3581","DOI":"10.1136\/bmj.k3581","article-title":"Prostate Cancer Screening with Prostate-Specific Antigen (PSA) Test: A Clinical Practice Guideline","volume":"362","author":"Tikkinen","year":"2018","journal-title":"BMJ"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.5489\/cuaj.7851","article-title":"Update\u20132022 Canadian Urological Association Recommendations on Prostate Cancer Screening and Early Diagnosis: Endorsement of the 2021 Cancer Care Ontario Guidelines on Prostate Multiparametric Magnetic Resonance Imaging","volume":"16","author":"Mason","year":"2022","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e077738","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate Cancer Incidence and Mortality in Europe and Implications for Screening Activities: Population Based Study","volume":"386","author":"Vaccarella","year":"2024","journal-title":"BMJ"},{"key":"ref_59","unstructured":"(2025, May 28). IARC Hosts Prostate Cancer Awareness and Initiative for Screening in the European Union (PRAISE-U) Consortium Meeting. Available online: https:\/\/www.iarc.who.int\/news-events\/iarc-hosts-prostate-cancer-awareness-and-initiative-for-screening-in-the-european-union-praise-u-consortium-meeting\/."},{"key":"ref_60","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2024). Cochrane Handbook for Systematic Reviews of Interventions, Cochrane. (updated August 2024)."},{"key":"ref_61","unstructured":"GRADE Working Group (2022, May 04). Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. Available online: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13643-022-02099-9","article-title":"Screening for Prostate Cancer: Protocol for Updating Multiple Systematic Reviews to Inform a Canadian Task Force on Preventive Health Care Guideline Update","volume":"11","author":"Bennett","year":"2022","journal-title":"Syst. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ilic, D., Neuberger, M.M., Djulbegovic, M., and Dahm, P. (2013). Screening for Prostate Cancer. Cochrane Database Syst. Rev., 2013.","DOI":"10.1002\/14651858.CD004720.pub3"},{"key":"ref_65","unstructured":"(DistillerSR, 2021). DistillerSR, Version 2.35."},{"key":"ref_66","unstructured":"Higgins, J., Savovi\u0107, J., Page, M., Elbers, R., and Sterne, J. (2021). Assessing Risk of Bias in a Randomized Trial. Cochrane Handbook for Systematic Reviews of Interventions, Wiley-Blackwell. Chapter 8."},{"key":"ref_67","unstructured":"(2023, December 21). Joanna Briggs Institute the Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for Prevalence Studies. Available online: https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI_Critical_Appraisal-Checklist_for_Prevalence_Studies2017_0.pdf."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bratt, O., Auvinen, A., Godtman, R.A., Hellstr\u00f6m, M., Hugosson, J., Lilja, H., Wallstr\u00f6m, J., and Roobol, M.J. (2023). Screening for Prostate Cancer: Evidence, Ongoing Trials, Policies and Knowledge Gaps. BMJ Oncol., 2.","DOI":"10.1136\/bmjonc-2023-000039"},{"key":"ref_69","unstructured":"(The Cochrane Collaboration Review Manager (RevMan) [Computer Program], 2014). The Cochrane Collaboration Review Manager (RevMan) [Computer Program], Version 5.3."},{"key":"ref_70","unstructured":"(2025, July 11). GRADE Handbook. Available online: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.ygojbnr1bi5y."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 Years of Followup in the Goteborg Randomized Population-Based Prostate Cancer Screening Trial","volume":"208","author":"Franlund","year":"2022","journal-title":"J. Urol."},{"key":"ref_72","first-page":"1299","article-title":"Estimating the Rate of Overdiagnosis with Prostate Cancer Screening: Evidence from the Finnish Component of the European Randomized Study of Screening for Prostate Cancer","volume":"32","author":"Walter","year":"2021","journal-title":"Cancer Causes Control"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1002\/cam4.3181","article-title":"Long-term Health-related Quality of Life among Men with Prostate Cancer in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"9","author":"Talala","year":"2020","journal-title":"Cancer Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.purol.2020.02.011","article-title":"Contamination in Control Group Led to No Effect of PSA-Based Screening on Prostate Cancer Mortality at 9 Years Follow-up: Results of the French Section of European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"30","author":"Villers","year":"2020","journal-title":"Prog. Urol."},{"key":"ref_75","first-page":"430","article-title":"Results of the Spanish Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 Years of Follow-Up","volume":"44","year":"2020","journal-title":"Actas Urol. Esp."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2018.10.053","article-title":"Results of Prostate Cancer Screening in a Unique Cohort at 19 Yr of Follow-Up","volume":"75","author":"Osses","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-18-1807","article-title":"The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)","volume":"25","author":"Pakarainen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ijc.32129","article-title":"Bias-Corrected Estimates of Effects of PSA Screening Decisions on the Risk of Prostate Cancer Diagnosis and Death: Analysis of the Finnish Randomized Study of Screening for Prostate Cancer","volume":"145","author":"Lindberg","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended Follow-up for Prostate Cancer Incidence and Mortality among Participants in the Prostate, Lung, Colorectal and Ovarian Randomized Cancer Screening Trial","volume":"123","author":"Pinsky","year":"2019","journal-title":"BJU Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.euo.2023.08.011","article-title":"From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life","volume":"7","author":"Hogenhout","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","article-title":"A Detailed Evaluation of the Effect of Prostate-Specific Antigen-Based Screening on Morbidity and Mortality of Prostate Cancer: 21-Year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer","volume":"84","author":"Meertens","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bju.16394","article-title":"Which Men Benefit from Prostate Cancer Screening? Prostate Cancer Mortality by Subgroup in the European Randomised Study of Screening for Prostate Cancer","volume":"134","author":"Pasanen","year":"2024","journal-title":"BJU Int."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Vickers, A.J., Sjoberg, D.D., Ulmert, D., Vertosick, E., Roobol, M.J., Thompson, I., Heijnsdijk, E.A., De Koning, H., Atoria-Swartz, C., and Scardino, P.T. (2014). Empirical Estimates of Prostate Cancer Overdiagnosis by Age and Prostate-Specific Antigen. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-26"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-Targeted or Standard Biopsy in Prostate Cancer Screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-Based, Randomised, Open-Label, Non-Inferiority Trial","volume":"22","author":"Nordstrom","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMc1515131","article-title":"Reevaluating PSA Testing Rates in the PLCO Trial","volume":"374","author":"Shoag","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early Detection of Prostate Cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening","volume":"210","author":"Wei","year":"2023","journal-title":"J. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.5489\/cuaj.8711","article-title":"Navigating Prostate Cancer Screening in Canada for Marginalized Men through PSA Screening and Guidelines Adherence: A Call to Action for Policymakers","volume":"18","author":"Bandara","year":"2024","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Albers, J.R., Brown, J.B., Charkowick, S.V., Ram, N., Klocksieben, F.A., and Kumar, A. (2022). Comparative Benefits and Risks Associated with Currently Authorized COVID-19 Vaccines. Vaccines, 10.","DOI":"10.3390\/vaccines10122065"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5489\/cuaj.9005","article-title":"Prostate Cancer Screening in Transgender Patients: Why Current Canadian Screening Policies Need to Be Better Tailored to Our Patients","volume":"19","author":"Nguyen","year":"2025","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.5489\/cuaj.8710","article-title":"Screening Guidelines for Individuals at Increased Risk for Prostate Cancer","volume":"18","author":"Lorentz","year":"2024","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_94","unstructured":"(2026, March 09). Cancer Care Ontario. Available online: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/221."},{"key":"ref_95","unstructured":"(2026, March 09). Prostate Specific Antigen (PSA) Testing|Cancer Research UK. Available online: https:\/\/www.cancerresearchuk.org\/health-professional\/diagnosis\/investigations\/psa-testing."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2025.3579","article-title":"Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial","volume":"333","author":"Kinnaird","year":"2025","journal-title":"JAMA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.euf.2016.10.009","article-title":"The Stockholm-3 (STHLM3) Model Can Improve Prostate Cancer Diagnostics in Men Aged 50\u201369 Yr Compared with Current Prostate Cancer Testing","volume":"4","author":"Eklund","year":"2018","journal-title":"Eur. Urol. Focus"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:24:25Z","timestamp":1775103865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":97,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040199"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040199","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}